SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Atomera, Inc. engages in the development, commercialization, and licensing of proprietary processes and technologies for the semiconductor industry. It developed Mears Silicon Technology, which increases performance and power efficiency in semiconductor transistors. The company was founded by Robert Mears on November 26, 2001 and is headquartered in Los Gatos, CA.

Atomera Inc

Atomera is seeing a surge in investor attention as the community anticipates news regarding potential Joint Development Agreements and commercial licensing deals tied to its Mears Silicon Technology, particularly within the Gate-All-Around and DRAM sectors. Traders are closely monitoring the stock's significant volume and price volatility, driven by speculation over partnerships with major semiconductor foundries and equipment manufacturers amid a broader focus on AI infrastructure.

POET Technologies, Inc. engages in the designing, developing, manufacturing and sale of opto-electronic solutions for the sensing, data communications and telecommunications markets. It developed POET Optical Interposer platform, which allows the integration of electronic and photonic devices into a single multi-chip module. The company was founded on November 14, 1985 and is headquartered in Toronto, Canada.

POET Technologies Inc

POET Technologies is seeing a massive surge in market interest, driven by speculation over potential partnerships with major hyperscalers and its critical role in AI optical interconnects. The community is actively discussing the stock's parabolic volume and momentum, with longs celebrating the potential for a sustained breakout while shorts remain under intense pressure.

Intellia Therapeutics, Inc. is a clinical stage genome editing company, which engages in the development of curative therapeutics using the CRISPR/Cas9 system. Its CRISPR/Cas9 system transforms medicine by both producing therapeutics that permanently edit and/or correct disease-associated genes in the human body with a single treatment course, and creates engineered cells that can treat oncological and immunological diseases. The company was founded by Andrew May, Luciano Marraffini, Rodolphe Barrangou, Nessan Bermingham, Rachel Haurwitz, Erik Sontheimer, Jennifer Doudna, and Derrick Rossi in May 2014 and is headquartered in Cambridge, MA.

Intellia Therapeutics Inc

Intellia Therapeutics is experiencing significant volatility and downward pressure as shareholders react to a recent shelf offering and concerns over clinical trial timelines. While the community remains polarized, with some investors accumulating shares on dips anticipating future trial data and a potential short squeeze, others are expressing frustration over the persistent selling and lack of clear upward momentum.

CRISPR Therapeutics AG is a gene editing company, which engages in the development of transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. Its CRISPR/Cas9 platform is a gene editing technology that allows for precise, directed changes to genomic DNA. The firm offers a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The company was founded by Rodger Novak, Emmanuelle Charpentier, Shaun Patrick Foy, Matthew Porteus, Daniel Anderson, Chad Cowan, and Craig Mellow on October 31, 2013 and is headquartered in Zug, Switzerland.

CRISPR Therapeutics AG

CRISPR Therapeutics is currently trending as retail investors react to a recent convertible notes offering, which triggered short-term volatility despite analysts viewing it as a move to strengthen the company's balance sheet for long-term R&D. The community remains deeply divided, with many long-term holders expressing frustration over price stagnation and leadership execution, while others highlight the company's $2 billion cash pile and upcoming clinical data catalysts as reasons to remain bullish.

Zebec's integrated products - real time payroll apps, on-chain payments infrastructure and networked DePIN - serve companies of all sizes, merchants and individuals and help transcend the boundaries of traditional banking and diminish the role of financial intermediaries.

Zebec Network

Zebec Network is gaining momentum as investors eye upcoming industry events and potential integration news, with the community actively debating the project's utility versus broader market volatility. Enthusiasts are focusing on long-term growth and technical accumulation, while discussion remains divided between those expecting significant adoption and others expressing caution over price trends.

Advanced Micro Devices, Inc. engages in the semiconductor business. Its products include processors, accelerators, graphics, adaptive SoCs, FPGAs, and SOMs, and software, tools, and apps. The firm offers artificial intelligence, industries, workloads, and gaming solutions. The company was founded by W. J. Sanders III on May 1, 1969 and is headquartered in Santa Clara, CA.

Advanced Micro Devices Inc.

Advanced Micro Devices Inc

AMD is surging alongside other semiconductor leaders as strong CPU performance data from Intel drives sector-wide momentum and investor FOMO. The community is actively debating whether this parabolic rally is a sustainable AI-driven breakout or an overextended bubble, with many traders focused on short squeezes and aggressive price action.

iShares Trust - iShares Semiconductor ETF

iShares Semiconductor ETF

The iShares Semiconductor ETF (SOXX) has captured significant community attention due to its historic streak of consecutive green sessions and parabolic price action, prompting intense debate over whether it represents a sustainable AI-driven bull run or an overdue blow-off top. Investors are actively discussing the risks of extreme overbought conditions while weighing tactical hedging strategies, such as using inverse ETFs, against a bullish narrative centered on unrelenting demand for AI infrastructure.

Rocket Lab Corp. engages in the development of rocket launch and control systems for the space and defense industries. It operates through the Launch Services and Space Systems segments. The Launch Services segment provides launch services to customers on a dedicated mission or ride-share basis. The Space Systems segment consists of spacecraft engineering and design services, spacecraft components, spacecraft manufacturing, and on-orbit mission operations. The company was founded by Peter Beck in 2006 and is headquartered in Long Beach, CA.

Rocket Lab Corp.

Rocket Lab USA Inc

Rocket Lab is currently gaining investor attention and upward momentum driven by consistent launch execution, a strong backlog of defense and space systems contracts, and anticipation surrounding the broader space sector's upcoming catalytic events. The community is actively discussing the company's competitive positioning as a vertically integrated prime contractor, with many investors focusing on successful mission deliveries while debating the impact of upcoming earnings and future growth prospects.

MaxLinear, Inc. engages in the provision of communications systems-on-chip (SoC) solutions used in broadband, mobile and wireline infrastructure, data center, and industrial and multi-market applications. Its products include cable broadband modems and gateways, wireline connectivity devices, radio frequency transceivers, fiber-optic modules, video set-top boxes and gateways, hybrid analog and digital televisions, direct broadcast satellite outdoor and indoor units, and power management and interface products. The company was founded by Kimihiko Imura, Curtis C. Ling, and Kishore V. Seendripu on September 25, 2003 and is headquartered in Carlsbad, CA.

MaxLinear Inc

MaxLinear is currently trending as traders aggressively reprice the stock following a significant earnings beat and raised guidance that highlights its growing role in AI-driven data center infrastructure. The community remains divided, with bulls pointing to fundamental momentum and institutional interest, while bears warn of a potential overvaluation and pump-and-dump mechanics after the recent parabolic price move.

VanEck ETF Trust - VanEck Semiconductor ETF

VanEck Semiconductor ETF

The VanEck Semiconductor ETF is experiencing intense volatility and record-breaking momentum, with community debate centered on whether this surge represents a sustainable AI-driven growth cycle or a speculative bubble reminiscent of the dot-com era. Traders are actively discussing the extreme technical overextension and concentration of the trade, with many weighing the risks of a blow-off top against the potential for continued upside from data center demand.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

iBio (IBIO) Projected to Post Quarterly Earnings on Friday

iBio (NASDAQ:IBIO) will be releasing its Q3 2026 earnings before the market opens on Friday, May 1. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2026-5-1-ibio-inc-stock-3...

iBio (NASDAQ:IBIO) Earns Buy Rating from Chardan Capital

Chardan Capital restated a "buy" rating and issued a $5.00 target price on shares of iBio in a report on Thursday...

iBio Details Generative AI Antigen Platform to Speed GPCR Antibody Discovery and Close Trust Gap

iBio (NASDAQ:IBIO) is seeking to narrow what it views as a growing trust gap between the promise of generative AI in drug discovery and the high cost and long timelines of bringing a drug to market...

<ul class="summary-bullets"><li>iBio stated that it expects to dose the first participant in Australia with IBIO-600 in the second quarter.</li><li>The company’s previously announced pre-clinical studies showed that IBIO-600 demonstrated a pharmacologic activity and an extended half-life of 40–52 days following a single administration in non-human primates.</li><li>iBio stated that it also observed an increase of over 5.1% in lean muscle mass during its pre-clinical studies.</li></ul>iBio Inc. (IBIO) shares gained nearly 10% in Wednesday’s pre-market trade after the company announced that its muscle-preserving drug has received approval for the first in-human trial in Australia.iBio stated that IBIO-600 has been approved by Australia’s Therapeutic Goods Administration (TGA) to initiate a Phase 1 study evaluating the safety, tolerability, pharmacokinetics, and pharmacodynamics of the drug in overweight and obese adult participants.Retail sentiment on Stocktwits around&nbsp;<a href="https://stocktwits.com/symbol/IBIO">iBio</a> trended in the ‘bullish’ territory at the time of writing.<h2 class="st-heading-2">First Participant Expected To Be Dosed In Q2</h2>iBio stated that it expects to dose the first participant in Australia with IBIO-600 in the second quarter (Q2).“While GLP-1 therapies have transformed the treatment landscape, significant gaps remain, particularly around the loss of muscle mass. We believe IBIO-600 has the potential to address this unmet need,” said iBio CEO Martin Brenner.iBio’s previously announced pre-clinical studies showed that IBIO-600 demonstrated a pharmacologic activity and an extended half-life of 40–52 days following a single administration in non-human primates.The company also observed an increase of over 5.1% in lean muscle mass during its pre-clinical studies.“These findings, observed alongside reductions in fat mass and durable effects over time, support the advancement of IBIO-600 into clinical development,” the company added.<h2 class="st-heading-2">What Does IBIO-600 Do?</h2>IBIO-600 is a long-acting monoclonal antibody that targets myostatin and GDF11, which are proteins that inhibit skeletal muscle growth.It is designed to help preserve lean muscle and improve body composition in patients with obesity. iBio stated that it has the potential to be used alongside GLP-1 treatments to counter muscle loss during weight reduction.<a href="https://stocktwits.com/symbol/IBIO">IBIO stock</a> is up 9% year-to-date and 40% over the past 12 months. The Vanguard Total Stock Market Index Fund ETF (VTI) is up 31% over the past 12 months, while the Vanguard Extended Market Index Fund ETF (VXF) is up 36% over the past 12 months.Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/dal-stock-soars-delta-air-lines-q1-results-beat-expectations/cZJODXcRIqr">DAL Stock Soars As Delta Air Lines Beats Q1 Expectations, CEO Says ‘Demand Remains Strong’</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

IBIO Stock Is Soaring Today After iBio's Muscle-Preserving Drug Receives Approval For Human Trial In Australia

iBio stated that IBIO-600 has been approved by Australia’s Therapeutic Goods Administration to initiate a Phase 1 study in overweight and obese adult participants.

Equity

iBio, Inc. (NASDAQ:IBIO) Given Average Recommendation of "Buy" by Analysts

iBio, Inc. (NASDAQ:IBIO - Get Free Report) has received a consensus recommendation of "Buy" from the six research firms that are presently covering the company, Marketbeat.com reports. One research...

iBio (NASDAQ:IBIO) Upgraded by Wall Street Zen to Hold Rating

Wall Street Zen upgraded iBio from a "sell" rating to a "hold" rating in a report on Saturday...

Insider Buying: iBio (NASDAQ:IBIO) CFO Buys 24,835 Shares of Stock

iBio, Inc. (NASDAQ:IBIO - Get Free Report) CFO Felipe Duran bought 24,835 shares of the stock in a transaction dated Thursday, March 19th. The stock was purchased at an average price of $2.02 per...

iBio (NASDAQ:IBIO) CFO Felipe Duran Acquires 24,835 Shares

iBio, Inc. (NASDAQ:IBIO - Get Free Report) CFO Felipe Duran bought 24,835 shares of the company's stock in a transaction dated Thursday, March 19th. The stock was purchased at an average price of...

Martin Brenner Purchases 12,336 Shares of iBio (NASDAQ:IBIO) Stock

iBio, Inc. (NASDAQ:IBIO - Get Free Report) insider Martin Brenner purchased 12,336 shares of the stock in a transaction dated Thursday, March 19th. The stock was purchased at an average cost of $2.02...

iBio (NASDAQ:IBIO) Cut to Sell at Wall Street Zen

Wall Street Zen lowered iBio from a "hold" rating to a "sell" rating in a research report on Saturday...

iBio, Inc. is an AI-driven innovator that develops next-generation biopharmaceuticals using computational biology and 3D-modeling of subdominant and conformational epitopes, prospectively enabling the discovery of new antibody treatments for hard to target cancers, and other diseases. It focuses on decreasing drug failures, shortening drug development timelines and opening up new frontiers against the most promising targets. The company was founded on April 17, 2008 and is headquartered in San Diego, CA.

IBIO
iBio Inc

Feed

News

Sentiment

Fundamentals

Info

Poll

Latest IBIO News

IBIOiBio Inc